IPO Year In Review: Late Rally Gives 50 Newly Public Biopharma Firms A 45.1% Average Return
Executive Summary
First-time offerings by drug developers fell from 2018 when 67 launched, but IPO investors’ fortunes improved with a year-end rally providing a 45.1% return versus a 7.5% loss in the prior year.
You may also be interested in...
Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
Galecto Joins 2020's NASDAQ Gold Rush With $85m Launch
Denmark-headquartered company’s lead candidate is an inhaled therapy for idiopathic pulmonary fibrosis.
Finance Watch: Biopharma VC Deals On Track For A Record-Breaking Year
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.